<p>GSK has bought from CureVac, the full rights to develop and manufacture vaccine candidates for influenza and Covid-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.</p><p>The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added.</p>.AstraZeneca's Covid prevention drug application gets EU fast-track assessment.<p>As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and Covid-19 in phase II clinical development and avian influenza in phase I clinical development.</p><p>The new deal includes CureVac getting an upfront payment of 400 million euros and up to 1.05 billion euros in milestone and royalty payments.</p><p><em>($1 = 0.9313 euros)</em></p>
<p>GSK has bought from CureVac, the full rights to develop and manufacture vaccine candidates for influenza and Covid-19 that use messenger RNA (mRNA) technology for up to 1.05 billion euros ($1.13 billion), it said on Wednesday.</p><p>The deal is the result of restructuring a collaboration, which began in 2020 to develop mRNA-based vaccines for infectious diseases, into a new licensing agreement, GSK added.</p>.AstraZeneca's Covid prevention drug application gets EU fast-track assessment.<p>As a result of the collaboration, the two companies have vaccine candidates for seasonal influenza and Covid-19 in phase II clinical development and avian influenza in phase I clinical development.</p><p>The new deal includes CureVac getting an upfront payment of 400 million euros and up to 1.05 billion euros in milestone and royalty payments.</p><p><em>($1 = 0.9313 euros)</em></p>